Liraglutide biosimilar (Tonghua Dongbao)

利拉鲁肽生物类似药（通化东宝）

Report date: 2025/09/11 15:51:35

Base Information

Drug NameLiraglutide biosimilar (Tonghua Dongbao)
Drug Alias Name统博力
ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Biosimilar
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2023/11/28
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTonghua Dongbao Pharmaceutical Co LtdTonghua Tongbo Biomedicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTonghua Dongbao Pharmaceutical Co Ltd
Inactive CompaniesTonghua Tongbo Biomedicine Co Ltd
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A